Telaprevir

Drug Profile

Telaprevir

Alternative Names: Incivek; Incivo; LY-570310; MP-424; Telavic; VX-950

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly; Vertex Pharmaceuticals
  • Developer Janssen R&D Ireland; Mitsubishi Tanabe Pharma Corporation; Vertex Pharmaceuticals
  • Class Antivirals; Cyclohexanes; Cyclopentanes; Cyclopropanes; Peptidomimetics; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 07 Jun 2016 Vertex terminates a phase I/II trial in Hepatitis C (Combination therapy, In adolescents, In children) in USA, United Kingdom, Belgium, Germany, Italy and Spain (NCT01701063)
  • 11 May 2016 Mitsubishi Tanabe Pharma Corporation terminates its co-development agreement for Telaprevir in Japan (Mitsubishi Tanabe Pharma Corporation, May 2016)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top